Amp Fund Performance since Jan 2017
At Amp, we research biopharma companies primarily with valuations between $200M and $5B, who have upcoming catalyst events in the next 12 months, and invest in some of these companies in the Amp Hedge Fund, LP, as well as a series of hypothetical funds where we test different strategies. The performance above is based on our hypothetical Amp 1.0 fund from January 1, 2017 to July 1, 2018, and since then based on our real hedge fund (Amp Fund, LP).
To learn more about Amp, see the About Amp page.
Amp Biopharma Investment Blog
Our free blog features periodic and shortened company and investment updates. Amp Core members get all updates and our full quarterly and company reports. Learn More
To view only our blog posts for biopharma investors that are a collaboration between Amp and our Double Helix Law IP team, CLICK HERE
Interested and want to learn more? Send us a note below.